Collaboration paves the way for improved interoperability.
Cloud-based medical image management company Ambra Health announced Tuesday it will partner with the vendor neutral artificial intelligence (AI) platform Arterys. It’s a move that will streamline interoperability and accelerate the use of AI applications, the companies said.
“We’re making AI real by improving the physician experience,” said John Axerio-Cilies, chief executive officer of Arterys. “We are increasing diagnosis, treatment accuracy, and ultimately outcomes that matter to patients and providers.”
Related Content: Columns from Morris Panner, Ambra Health CEO
This partnership brings together Arterys’ seven AI solutions that have been cleared by the U.S. Food & Drug Administration, including Cardio AI, Lung AI, and Neuro AI, with Ambra’s interoperable, customizable cloud platform that consolidates multiple imaging systems that allows for secure access to imaging data anywhere, anytime.
Bringing together Arterys’ AI applications and Ambra’s platform opens the door for improved research and development, as well as patient care, said Ambra officials.
“Arterys has demonstrated that AI has rapidly moved from theory to practice. But, in order for AI programs to be effective, imaging data can’t operate in silos or disparate systems,” said Andrew Duckworth, Ambra Health vice president of business development. “By partnering with Arterys, we’re making it seamless for physicians to layer on innovative AI solutions to their existing Ambra cloud technology.”
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.